Don’t be deceived if there’s a collective yawn today from the financial world in reaction to the drug price-fixing decisions being announced today. 🧵(1/6)
These older drugs face stiff competition from therapeutic alternatives and already give significant rebates to pharmacy benefit managers to get covered. (2/6)
There are real issues with drug prices and how we pay for drugs, but this is a terrible solution to an aspect of drug pricing where competition actually drives down net prices. (3/6)
The real impact of this solution in search of a problem will come in future decades as new molecules aren’t developed, drugs are not studied for multiple indications, cancer drugs are not studied as first-line therapies, drugs for rare diseases aren’t invested in, (4/6)
more expensive injectables (which get more years before price fixing) are prioritized over cheaper pills, launches of drugs are delayed to develop the full suite of indications before starting the clock on price fixing, and new drugs get launched first outside the U.S., (5/6)
denying access for U.S. patients. The potential consequences to human health could be very grave. (6/6)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
